Celcuity Inc, a targeted diagnostics company, operates on a unique business model focusing on developing and commercializing novel companion diagnostic tests. By analyzing a patient's living cancer cells used in diagnostic testing, Celcuity gathers crucial data to identify abnormal signaling pathways that can guide physicians in selecting the most effective treatment. Leveraging its proprietary CELsignia platform, Celcuity aims to improve patient outcomes by enabling the identification of patients who are likely to respond favorably to specific targeted therapies. Through its innovative approach, Celcuity strives to revolutionize personalized medicine in the field of cancer diagnostics.

Celcuity Inc is primarily active in the biotechnology industry.

The main competitors of Celcuity Inc in the market are large pharmaceutical companies such as Pfizer, Novartis, and Roche.

Celcuity Inc is a biotechnology company based in Minneapolis, Minnesota. Founded in 2012, Celcuity focuses on developing innovative therapeutic solutions for the treatment of cancer. The company specializes in discovering cancer subtypes by analyzing a patient's cells to identify abnormal signaling activity. By providing this personalized information, Celcuity aims to help healthcare professionals make more informed treatment decisions. With its cutting-edge platform and collaborations with renowned institutions, Celcuity Inc is committed to advancing precision medicine and improving patient outcomes in the field of oncology.

Celcuity Inc has achieved several significant milestones in its journey. The company has made remarkable progress in the field of precision medicine and oncology diagnostics. One of the notable achievements includes its successful initial public offering (IPO), which helped to raise funds for further research and development efforts. Moreover, Celcuity has successfully established collaborations with renowned academic institutions and pharmaceutical companies, allowing for the expansion of its product pipeline and access to a broader patient population. The continued advancements in their proprietary CELsignia platform have also provided valuable insights into the molecular signatures of various cancers, enhancing physicians' ability to personalize treatment strategies.

Celcuity Inc is primarily present in the United States.

Celcuity Inc represents the values of innovation, precision, and patient-centered care. As a biotechnology company, Celcuity is dedicated to developing and commercializing novel diagnostic tests to identify and treat cancer patients who can benefit from targeted therapies. Their corporate philosophy emphasizes the importance of using cutting-edge technology to improve patient outcomes and provide physicians with precise and actionable information. By harnessing the power of CELsignaling™, Celcuity strives to revolutionize therapeutic decision-making in oncology. Through their relentless pursuit of scientific advancements, Celcuity Inc aims to make a significant and positive impact in the field of precision medicine.

Analysts currently set an average price target of 115,26 USD for the Celcuity stock (median: 114,75 USD), implying +25,7 % versus the latest price. The consensus is based on 17 analyst ratings.

Celcuity Analyytikkojen kursstavoitteet 2026

17 analysts currently rate the Celcuity stock: 15 recommend buying, 2 holding and 0 selling. For 2026, analysts expect Celcuity to generate revenue of 44,91 M USD and earnings per share of −4,16 USD.

Celcuity Analyytikkojen kursstavoitteet 2026

Converted at the current exchange rate, the Celcuity share trades at 80,35 EUR (91,69 USD).

The Celcuity share (CELC) is listed on 1 stock exchanges, including: NASDAQ (CELC).

Celcuity Inc is a US biotechnology company specializing in the development of precision medicine solutions for the treatment of cancer. The company was founded in 2012 and is headquartered in Minneapolis, Minnesota. Celcuity operates in two business areas: drug development and diagnostic test development. Celcuity's drug development is based on the discovery of new mechanistic target molecules that play a role in cancer formation. The company is working intensively to develop drugs that specifically target these targets to achieve better efficacy and tolerability in cancer therapy. The second business area is the development of diagnostic tests. Celcuity has developed a novel diagnostic procedure that identifies the molecular signature of cancer cells, enabling rapid and targeted diagnosis. These tests can help identify patient groups most likely to benefit from specific cancer treatments, leading to better and personalized therapies. Celcuity already offers various diagnostic tests, including the CELx HER2 Signaling Function Test, which measures the HER2 signaling pathway in tumor cells, allowing prediction of the efficacy of various HER2-targeted therapies. Celcuity's business model is based on the development of innovative solutions based on precision medicine approaches. The company collaborates with renowned research institutions and pharmaceutical companies. Celcuity is a publicly traded company financed through the sale of shares. The company has invested significantly in research and development in recent years and has acquired several patents to protect its technology. Celcuity aims to improve the lives of cancer patients through the development of better treatment options and a personalized approach. Collaboration with the medical community and the development of innovative diagnostic tests are key priorities. Overall, Celcuity is a promising biotechnology company leading in the field of precision medicine for cancer therapy. The company has made significant progress in recent years and is committed to revolutionizing cancer therapy through the provision of personalized treatments.

odotettu liikevaihto Celcuity on 44,91 M USD. Tämä luku perustuu nykyisiin talousarvoihin ja heijastaa yhtiön liiketoimintasuoritusta.

odotettu voitto Celcuity on −164,18 M USD. Nettovoitto kuvastaa yhtiön kannattavuutta kaikkien kulujen vähentämisen jälkeen.

Celcuity:n hinta-voitto-suhde (P/E) on tällä hetkellä −22,03. P/E-suhde vertaa nykyistä osakekurssia osakekohtaiseen tulokseen ja auttaa sijoittajia arvioimaan Celcuity-osakkeen arvostusta.

Celcuity:n hinta-myynti-suhde (P/S) on tällä hetkellä 80,53. P/S-suhde vertaa markkina-arvoa vuosittaisiin tuloihin ja toimii Celcuity-osakkeen arvostuskennuslukuna.

Celcuity:n Eulpool-laatuscore on 2/10.

Celcuity:n ISIN on US15102K1007. ISIN (International Securities Identification Number) on maailmanlaajuisesti ainutlaatuinen arvopaperin tunnus.

Celcuity:n WKN on A2JAAX. WKN (Wertpapierkennnummer) on kuusinumeroinen saksalainen arvopaperin tunnus.

Celcuity:n ticker on CELC. Tämä pörssinoteeraus käytetään Celcuity-osakkeiden kauppaan pörssissä.

Celcuity maksoi osinkoa joka vuosi viimeisten 0 vuoden aikana.

Celcuity kuuluu sektoriin 'Terveydenhuolto'.

Celcuity:n osingot jaetaan valuutassa USD.